⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INKT News
MiNK Therapeutics, Inc. Common Stock
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
globenewswire.com
INKT
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
globenewswire.com
INKT
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
globenewswire.com
INKT
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
globenewswire.com
INKT
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
globenewswire.com
INKT
Form 8-K
sec.gov
INKT
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
globenewswire.com
INKT
Form 8-K
sec.gov
INKT
Form 8-K
sec.gov
INKT
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
globenewswire.com
INKT